🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial thelancet.com/journals/lance…

Congrats to Prof Saskia Middeldorp and colleagues for presenting the ALIFE2 trial at the next ASH meeting. The use of LMWH did not result in higher live birth rates in women who had ≥2 pregnancy losses and thrombophilia ash.confex.com/ash/2022/webpr… Can't wait to see the talk!

RCT from Prof Ageno et al reported that anticoagulation for 12 weeks (vs. 6) for symptomatic distal DVT is associated with lower risk of recurrent events (mostly recurrent distal DVT) without increasing the risk of bleeding #MedTwitter Thrombosis Canada bmj.com/content/379/bm…

How many landmark trials, critical to the practice of obstetric-thrombosis, can Saskia Middeldorp put out in a single year?! Absolutely incredible!

The Vascular 2023 Call for Science is now live! Take advantage of this opportunity to showcase your work on the #VASC23 stage. You have until May 2, 2023 to submit your abstract here: ow.ly/T8SS50N17yU. Visit vascular2023.ca to learn more. #CCCongress

We know antithrombotic drugs (like aspirin, heparin, tenecteplase) can all cause bleeding But they also have some very unusual side effects… like hyperkalemia, asthma, and skin necrosis A thread🧵 Thanks to Ismail Raslan and Eric Kaplovitch for inspiration

Learn about managing #PAD with our upcoming webinar, Peripheral Arterial Disease: Management, taking place next Friday, March 31 @ 12 PM EDT. Panelists include Drs. Sonia Anand, Eric Kaplovitch, John Mancini, Hassan Mir & Darryl Wan. Register today: ow.ly/qgEq50NrjrX

Absolutely what we see (anecdotally) here too! Next Q is optimal dose and duration! we see fair bit of breakthrough on proph dose -tend to go for at least intermed dose for real SVTs, usually until 6 wks PP Wonder about others’ practice Saskia Middeldorp Isabelle Malhamé Eric Tseng

Yes!

Women aged 50-64 were studied to assess risk of #VTE by exposure to menopausal hormone therapy. Cases were matched to controls 1:10 & multivariable models suggested large⬆️ in risk with oral HT & contraceptive HT, but no risk with transdermal HT. bit.ly/41Aq87n @Utmbspph

📣Publication alert: finally published in The Lancet , the ALIFE2 trial. So thankful to all women who participated and all colleagues who joined the study. LMWH does NOT improve live birth in women with #thrombophilia and #recurrent miscarriage. thelancet.com/pb-assets/Lanc…

ICYMI in the 📕#RedJournal: Periprocedural Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant Undergoing a Digestive Endoscopy Hansen-Barkun, et al. 👉 bit.ly/42q0PFw Neena S Abraham MD MACG FASGE AGAF Eric Kaplovitch Alex Spyropoulos Alan Barkun

🚨📢 Continuing txt with the SAME DOAC was MORE EFFECTIVE at preventing recurrent ischemic stroke VS. switching to a different DOAC (aHR 1.62, 95%CI 1.25-2.11, p-value <0.001) or to warfarin (aHR 1.96, 95%CI 1.27-3.02, p=0.002) 🚫 role for antiplatelets n.neurology.org/content/early/…

Obstetric and perioperative management of patients with factor #XI deficiency: a retrospective observational study ashpublications.org/bloodadvances/…

In a large cohort (n=669) of patients after #PFO device closure we observed no differences in short and long-term (FU=11.6y) outcomes b/in those w/wo thrombophilia. Ada C. Stefanescu Schmidt, MD MSc FACC Dr. Eric Horlick Douglas Lee @PMCC #ICES| JACC: Cardiovascular Interventions jacc.org/doi/10.1016/j.…

The risk of DOAC related bleeding in patients with cirrhosis is no higher than with other anticoagulants (and may be lower). Meta-analysis of 29 studies which included 2469 patients with cirrhosis receiving DOAC anticoagulation. tinyurl.com/4mpzvy5j #thrombosis #DOAC

We should probably be doing CDT more (for very proximal DVT and severe symptoms in particular)

Heparin resistance remains a poorly defined phenomenon but #Covid_19 taught us its importance Defining Heparin Resistance: Communication from the ISTH SSC Subcommittee of Perioperative and Critical Care Thromb… pubmed.ncbi.nlm.nih.gov/37619694/

Great Review!

BREAKING from NEJM In cancer patients w/ Cancer-Associated Venous Thromboembolism, reduced-dose apixaban (2.5 mg BID) is : 🔘Noninferior to full-dose (5 mg BID) for VTE recurrence 🔘Lower bleeding risk (12.1% vs. 15.6%) 🔘Safer extended anticoagulation, same protection.